Primary spindle cell sarcoma of gallbladder
An unusual case report and a literature review

Xin Long, MDa, Yan Chen, MDb, Wei-Xun Chen, MDa, Yu Wu, MDa, Jia Song, MDa, Jin Chen, MDa, Lei Zhang, MDa,c,*

Abstract

Introduction: Primary spindle cell sarcoma of the gallbladder is a rare condition.

Patient concerns: A 67-year-old woman was admitted to a local hospital with a chief complaint of abdominal pain in the right upper quadrant for the past 2 months.

Diagnosis and intervention: Surgical resection was performed following the diagnosis of primary gallbladder sarcoma with local hepatic metastasis. Histological examination confirmed a diagnosis of primary spindle cell sarcoma and hepatic metastasis with simultaneous cholecystolithiasis.

Outcomes: Adjuvant chemoradiation therapy was not performed because the patient refused treatment. Three months after the surgery, a relapsed lesion was diagnosed. The patient underwent transcatheter arterial chemoembolization.

Conclusions: The disease should be differentially diagnosed from gallbladder carcinoma or carcinosarcoma with hepatic metastasis. An aggressive surgical approach should be based on a balance between the risk of surgery and the outcome.

Abbreviations: CT = computed tomography, MDT = multidisciplinary team, MRI = magnetic resonance imaging, MSC = mesenchymal stem cells, NGS = next-generation sequencing.

Keywords: diagnosis, gallbladder, gallbladder carcinoma, primary spindle cell sarcoma, surgical treatment

1. Introduction

Soft tissue sarcomas are rare solid tumors of mesenchymal cell origin that exhibit a heterogeneous mix of clinical and pathological characteristics. They account for 1% of adult cancers and 10% to 20% of adolescent and young adult cancers.[1] With the widespread use of regular medical checkups and improvements in early diagnosis, the occurrence of primary sarcoma of the gallbladder is becoming more frequent.[2] However, knowledge concerning the clinical features and outcomes of primary sarcoma of the gallbladder remains limited. Here, we report a case of primary spindle cell sarcoma with hepatic metastasis.

2. Case presentation

A 67-year-old woman was admitted to a local hospital with a chief complaint of abdominal pain in the right upper quadrant for the past two months. A multidetector computed tomography (CT) scan of the abdomen showed a thickened gallbladder wall with gallbladder stones and multiple hypodense tumorous lesions adjacent to the gallbladder in the lower part of segments IV and V of the liver. Emission computed tomography revealed no bone metastases. A biopsy of the liver lesion was performed at a local hospital. Histopathological examination revealed the possibility of a metastatic inflammatory myofibroblastic tumor originating from the gallbladder. The patient was then transferred to our hospital for further diagnosis and treatment.

The patient had a history of high blood pressure for 2 years: which was controlled by oral administration of amlodipine and telmisartan. There was no remarkable family, medical, or genetic history. The patient was in good general health and had undergone a significant weight loss. Her vital signs (heart rate, respiration rate, blood pressure, and body temperature) were within the normal limits. No positive signs were observed during...
physical examination. The complete blood count and serum biochemistry data on admission were normal. The patient also showed normal levels of tumor markers, including alpha-fetoprotein (AFP: 0.87 ng/ml, normal: ≤7 ng/ml), carcinoembryonic antigen (CEA: 2.09 ng/ml, normal: ≤5.0 ng/ml), and carbohydrate antigen19-9 (CA19-9: 0.90 U/ml, normal: ≤34 U/ml).

Magnetic resonance imaging (MRI) with perfusion-weighted imaging confirmed the presence of gallbladder stones (the largest measured 3.5 × 2.1 cm) and thickened wall in the enlarged gallbladder (13.5 × 9.9 cm), and hypervascular tumors in the liver (Fig. 1A–F). The abdominal ultrasonography data were consistent with these data (Fig. 2A–C). Thus, the preoperative diagnosis was a primary sarcoma of the gallbladder with hepatic metastasis. A multidisciplinary team (MDT) was composed of a variety of specialists who each brought a perspective to the holistic management of this patient, including surgeons, medical oncologists, radiation oncologists, pathologists, radiologists, gastroenterologists, and ultrasonologists. After the MDT discussion, the decision was made to remove the gallbladder and invaded liver tissues.

The patient was informed of the risks involved with the surgery before consent for the operation was obtained. After preoperative preparation, the patient underwent exploratory laparotomy. During laparotomy, the gallbladder was enlarged, showed wall thickening, and had numerous stones (the largest measuring 6 × 6 cm). Exploration also indicated an 8 × 6 cm rigid lesion fused by multiple masses in liver segments IVb and V. All of these formed a mass of 14 × 10 cm. In addition, the tumor invaded the serosa of the colon transversum and duodenal bulb, as well as the pancreatic capsule. Enlarged lymph nodes were not observed. The patient underwent cholecystectomy, resection of liver segments IV and V, and regional lymphadenectomy.

Postoperative histopathological examination confirmed primary spindle cell sarcoma and hepatic metastasis, with simultaneous cholecystolithiasis (Fig. 3), which included heterogeneous, moderately differentiated features, most probably originating from fibrogenic or myofibrogenic sources, with an organizational structure akin to an inflammatory myofibroblastic tumor with focal necrosis. The lymphoid nodes in groups 12a, 12b, 12c, 8, and 13 showed no neoplastic cells. Immunohistochemical examination revealed positive expression of SDHB, cyclin D1, S-100 (focal), β-catenin (cytoplasmic), and MDM2 (in part). The tumor was negative for CD 163, CD68, PCK, ALK, ROS1, CD117, CD34, DOG1, SMA, DES, Caldesmon, SOX100, MSA, EMA, CK18/8, CK19, CD1a, CD21, CD23, CD35, langerin, CD45-LCA, HMB45, Melan-A, Braf (V600E), and E-cadherin. Molecular pathology showed that EBER FISH was negative.
After 10 days of recovery, the patient was discharged without any complications. Adjuvant chemoradiation therapy was not administered because of the patient’s refusal to consent. Three months after the surgery, the patient underwent ultrasonography and MRI. Both examinations implied that there was a relapsed lesion (4 × 5 cm) in segment VIII. The patient underwent the treatment involving transcatheter arterial chemoembolization. The patient was discharged after 4 days. In the 11-month period since the second intervention, the patient was asymptomatic and had satisfactory general health, as confirmed by telephone interviews at 2-month intervals. More detailed information about the patient could be found in Table 1.

| Cases | Case number | Age (yrs)/sex | Gallbladder stones | Location of tumor in liver | Histopathological examination | Treatment | Prognosis (mo)
|-------|-------------|---------------|--------------------|-----------------------------|--------------------------------|-----------|---------------------
| Perez-Montiel D et al[4] | 1 | 34/F | With | No | LMS | Laparotomy | 24/Alive
| Olgay G et al[5] | 1 | 61/F | With | No | EOS | Laparotomy | 9/Death
| Shankar A et al[6] | 1 | 45/F | With | No | EOS | Laparotomy | 12/Alive
| Paach C et al[7] | 24 | 66.8 ± 15.3; MF:6/18 | With (12) | Without (12) | 4: SV, SVV, SIV/V; N/A | LMS | Laparotomy: 15; Chemotherapy: 1; Drainage: 1; Laparotomy: 15; Death (8): 3-30; Death (6): 1.9 ± 2.1
| Garcia Marín A et al[8] | 2 | 79/M 81/F | N/A | Bilobar | LMS | Laparotomy | 0.03, 0.23
| Zhao G et al[9] | 1 | 74/F | Without | No | LCS | Laparotomy | 8/Alive
| Bader H et al[10] | 1 | 79/M | Without | No | liposarcoma | Laparotomy | 24/Death
| Hamada T et al[11] | 1 | 49/F | Without | No | liposarcoma | Laparotomy | 3/Alive
| Ma Y et al[12] | 1 | 70/F | Without | No | liposarcoma | Laparotomy | N/A
| da Costa AC et al[13] | 1 | 71/F | With | No | liposarcoma | Laparotomy | 8/Alive
| Al-Daraji W et al[14] | 15 | A: 65.3 ± 19.2 | With (10) | N/A | MFHV: 8 | Laparotomy: 15; Chemotherapy: 3; Radiation: 2; Death (15): 132,324; N/A (3)
| A: 12; C: 1.5, 1.8, 3; | 12 | MF: 4/11 | | | | | 
| C: 3 | | | | | | | 
| Liu XF et al[15] | 1 | 72/F | Without | No | LMS | Laparotomy | 2; Chemotherapy: 3; Radiation: 2; Death (10): 15.5 ± 20.9; N/A (3)
| Oda Hiro AN et al[16] | 7 | 67.4 ± 13.0; MF: 4/2 | With (5) | N/A | AS | Laparotomy | N/A
| Costantini R et al[17] | 1 | 57/M | With | No | AS | Laparotomy | 60/Alive; Death (6): 1.8 ± 1.5
| Sánchez Acosta P et al[18] | 1 | 81/M | Without | SV | AS | Laparotomy: 7; All death: 1.5-24
| Husain EA et al[19] | 7 | 72.1 ± 7.4; MF: 1/6 | Most | N/A | MFHV: 3 | Laparotomy | N/A
| AS: 1 | | | | | | | 
| AS: 2; Liposarcoma: 2 | | | | | | | 
| Qayum A et al[20] | 1 | 51/M | Without | No | SCS | Laparotomy and radiation | N/A
| Nestler G et al[21] | 1 | 66/M | Without | No | Myogenous sarcoma | Laparotomy | 2 laparotomy; 11/Death
| Gahlot GP et al[22] | 1 | 72/F | With | No | EOS | Laparotomy | N/A
| Present case | 1 | 67/F | With | SIV/V | Spindle cell sarcoma | Laparotomy | 12/Alive

A = adult, AS = angiosarcoma, C = children, EOS = extraskeletal osteosarcoma, F = female, LCS = Langerhans cell sarcoma, LMS = leiomyosarcoma, M = male, MFHV = malignant fibrous histiocytoma variants, RMS = rhabdomyosarcoma, S = segment, SCS = synovial cell sarcoma.

* Thirty days in 1 month.

† Both were children with RMS, the other was lost to follow-up.
not be obtained because the patient refused to consent to new imaging tests.

### 3. Discussion and conclusions

Primary sarcoma of the gallbladder is a rare form of tumor compared with other malignancies of the gallbladder and represents approximately 1.5% of all malignant gallbladder diseases. A variety of tumors composed of sarcomatous elements include carcinosarcoma and 11 types of primary sarcoma (extraskeletal osteosarcoma, Langerhans cell sarcoma, synovial cell sarcoma, rhabdomyosarcoma, malignant fibrous histiocytoma variants, leiomyosarcoma, angiosarcoma, neurofibrosarcoma, myogenus sarcoma, and liposarcoma) (Tables 1 and 2). To date, there have been 65 cases reported in English outlets.[4–22] Table 1 presents the results.

According to the World Health Organization classification of soft tissue and bone tumors, there are more than 50 different histologic subtypes of sarcomas.[23] Nearly one-quarter of these types have been found in primary sarcomas of the gallbladder. Based on our data, this was more frequent in women with an M/F ratio of 1.2:42. It occurred at all ages, from 1.5 years to 91 years, with the highest frequency occurring between the ages of 50 and 90 years (approximately 84.6% of all cases). Gallstones are invariably present in several types of primary sarcomas of the gallbladder (Tables 1 and 2), and the presenting symptoms are those of chronic cholecystitis.[4–22]

In this series of 65 cases reviewed in the literature, no case was correctly diagnosed before surgery, except when it was preoperatively diagnosed by biopsy. CT and MRI are considered to be the best diagnostic techniques for cancer staging and surgical strategy guidance. However, the data indicate that in sarcomas, the rate of diagnostic inaccuracy ranges between 20% and 30%. The reasons for this may be

1. low incidence and lack of experience,
2. lack of obvious symptoms and typical radiological features, and
3. non-specific tumor markers.

Apart from these cases, it might also have been due to the intrinsic complexity of sarcoma, technological complexity, and the lower influence of educational efforts. We considered it difficult to differentiate between primary sarcoma, carcinosarcoma, and carcinoma of the gallbladder; therefore, we searched the literature and listed the main differences between the most common tumors of the gallbladder in Table 3.[23–29] Recently, studies have shown that positron emission computed tomography scanning is useful in differentiating malignant from benign diseases when using various radiopharmaceutical agents to improve the detection and characterization of the pathophysiology of the disease.[30] The fusion of positron emission computed tomography-acquired images with CT scans or MRI has significantly improved the overall diagnostic accuracy for sarcoma.[31] Histopathology from biopsy or liver resection remains the gold diagnostic standard. If the lesions can be surgically resected, histological examination of the whole lesion is more reliable than a biopsy because insufficient, missed, or ample necrotic tissues may not be representative of the entire lesion.[32] Needle-tract implantation and complications (such as prolonged internal bleeding, bile leakage, and infection) are other reasons why preoperative biopsy of the liver is not recommended.[34] The detailed diagnostic procedure is shown in Figure 4.
MDT in oncology is defined as cooperation between different specialized professionals involved in cancer care with the overarching goal of improving treatment efficiency and patient care. MDT discussion is conducive to prompt diagnosis and rapid referral, and provides patient-centered, specialized, integrated multidisciplinary care and treatment. Based on the suggestions from the MDT, we decided to implement surgical therapy because curative resection, if possible, most effectively prolongs patient survival. Most of the patients with sarcoma of the gallbladder underwent surgical treatment, and several were

Table 3
Differential diagnosis between primary sarcomas of gallbladder, carcinosarcoma of gallbladder and gallbladder carcinoma with hepatic metastasis.

|                    | PSG                      | CG[25–28]                  | GC with HM[29]               |
|--------------------|--------------------------|----------------------------|------------------------------|
| Incidences         | Rare, 65 cases (no 3 children) | Rare, about 100 cases, <1% of gallbladder cancer | Geography/ethnicity (1.1–27/10^7) |
| Gender             | Major in F (F/M = 2.4/1) | Major in F (F/M = 4.3/1) | Major in F (F/M = 2–6/1) |
| Age (yrs)          | Old age (Mean = 68.8) | Old age (Mean = 68.8) | Old age (mean = 67) |
| HBV/HCV            | Partial patients         | N/A                       | Not                          |
| Gallbladder stones | 50%                      | 33–75%                    | ~85%                         |
| AFP                | Not                      | Not                      | Not                          |
| CEA                | Not                      | Not                      | Elevated                     |
| CA19-9             | Not                      | Not                      | Elevated                     |
| Number of liver masses | Simple or multiple | Simple or multiple | Multiple                     |
| Location of liver masses | Any segments in the liver | Most adjacent to the gallbladder | Adjacent to the gallbladder |
| Invasion of GC     | Not found                | Often                     | Presentation                 |
| Imaging manifestation | Hypovascular or hypervascular | Hypervascular            | Hypovascular                |

AFP = alpha-fetoprotein, CA19-9 = carbohydrate antigen 19-9, CEA = carcinoembryonic antigen, CG = carcinosarcoma of gallbladder, F = female, GC = gallbladder carcinoma, HBV = hepatitis B virus, HCV = hepatitis C virus, HM = hepatic metastasis, M = male, and PSG = primary sarcomas of gallbladder.

Figure 4. Clinical algorithms for the evaluation of primary sarcoma of gallbladder. AFP = alpha-fetoprotein, CA125 = carbohydrate antigen125, CEA = carcinoembryonic antigen, CT = computed tomography, ECT = emission computed tomography, MRI = magnetic resonance imaging, NGS = next-generation sequencing, and PET-CT = positron emission computerized tomography.
further treated with adjuvant chemotherapy and/or radiation (Tables 1 and 2); however, the prognosis was not satisfactory; more than half of the patients died within 8.8 ± 14.7 months after surgery, which might be higher due to partial loss of follow-up opportunities, making this a concern for surgeons and oncologists about how to treat patients with this rare disease.

The pathogenesis of sarcoma of the gallbladder has not been clarified, and some factors, such as germline mutations, radiation, and environmental exposure, are involved. Gallbladder stones and/or infective agents cause cancer as a result of recurrent trauma and chronic inflammation. In our study, 59.6% of patients were diagnosed with cholecystolithiasis, but it remains unclear whether gallbladder stones and concomitant inflammation initiate the transformation of mesenchymal cells. Many studies have shown that sarcoma might originate from mesenchymal stem cells (MSCs), which show that rodent MSCs are prone to spontaneous sarcomagenesis upon prolonged in vitro culture, and that MSCs have been used to establish several crucial experimental sarcoma models. The rarity of the disease means that clinical data are limited; therefore, the detailed etiology and mechanism still need further clarification. Recently, next-generation sequencing (NGS) has been recommended for application in oncology, spanning from diagnostics to prognosis and from prevention to treatability. NGS techniques have provided additional insights into the genetic diversity and complexity of sarcomas, including the potential therapeutic implications of some genetic alterations. In this study, the patients refused NGS and adjuvant chemotherapy because of economic limitations and doubts regarding adverse reactions to chemotherapy.

In conclusion, primary sarcomas of the gallbladder are rare. Owing to the lack of apparent radiological features, it is not easily differentiated from other types of gallbladder tumors. Therefore, it is necessary to develop more accurate diagnostic techniques and administer more refined treatment strategies to diagnose and treat this disease.

Acknowledgments

The authors thank MD Chao-Hong Yu for his assistance with language checking and revision.

Author contributions

PX, CY and ZL designed the study and wrote the manuscript. CWX, WY, SJ, and CJ participated in study design, data collection, and drafting of the manuscript. PX, CY, and ZL participated in language checking. All authors have read and approved the manuscript.

Conceptualization: Xin Long, Yan Chen, Lei Zhang.

Data curation: Jia Song.

Formal analysis: Jin Chen.

Methodology: Wei-Xun Chen, Yu Wu, Jia Song.

Supervision: Lei Zhang.

Writing – original draft: Xin Long, Yan Chen, Lei Zhang.

Writing – review & editing: Lei Zhang.

References

[1] Poon E, Quak R. Soft tissue sarcoma in Asia. Chin Clin Oncol 2018;7:46.
[2] von Mehren M, Randall RL, Benjamin RS, et al. Soft tissue sarcoma, version 2.2018, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 2018;16:536–63.
[3] Gamboa AC, Gronchi A, Cardona K. Soft tissue sarcoma in adults: an update on the current state of histotype-specific management in an era of personalized medicine. CA Cancer J Clin 2020;70:200–29.
[4] Perez-Montiel D, Mucientes F, Spencer L, Klaassen R, Suster S. Polyoid leiomyosarcoma of the gallbladder: study of a case associated with adenomyomatous hyperplasia. Ann Diagn Pathol 2009;13:538–63.
[5] Olgyay G, Horváth V, Banga P, Kocsis J, Buza N, Oláh A. Extraskellet osteosarcoma located to the gallbladder. HPB (Oxford) 2006;8:65–6.
[6] Shankar A, Saloo RK, Malik A, Kakkar A, Kishor Rath G. Extra skeletal osteosarcoma of gall bladder: a case report. J Egypt Natl Canc Inst 2015;27:231–4.
[7] Pascale C, Talak M, Mairinger T, Theissig F. Leiomyosarcoma of the gallbladder – a case report and a review of literature. Int J Surg Case Rep 2020;66:182–6.
[8] García Marín A, Bernardos García L, Martín Gil J, de Colsa DS, Fuentes FT. Primary leiomyosarcoma of the gallbladder. Rev Esp Enferm Dig 2010;102:67–8.
[9] Zhao G, Luo M, Wu ZY, et al. Langerhans cell sarcoma involving gallbladder and peritoneal lymph nodes: a case report. Int J Surg Pathol 2009;17:347–53.
[10] Bader H, Vallon H. Liposarcoma of the gallbladder and the peritoneum. A case report. Zentralbl Allg Pathol 1983;127:45–9.
[11] Hamada T, Yamagawa K, Okanami Y, et al. Primary liposarcoma of gallbladder diagnosed by preoperative imagings: a case report and review of literature. World J Gastroenterol 2006;12:1472–5.
[12] Ma Y, Wei S, Peker D. An extremely rare primary gallbladder myxoid liposarcoma associated with amplification of DDIT3 gene. J Gastrointest Liver Dis 2014;23:460–1.
[13] da Costa AC, Santa-Cruz F, Sena BF, et al. Dedifferentiated liposarcoma of the gallbladder: first reported case. World J Surg Oncol 2018;16:223.
[14] Al-Daraji WI, Makhlouf HR, Miettinen M, et al. Primary gallbladder sarcoma: a clinicopathological study of 15 cases, heterogeneous sarcomas with poor outcome, except pediatric botryoid rhabdomyosarcoma. Am J Surg Pathol 2009;33:826–34.
[15] Liu XF, Tang K, Sui LL, Xu G. Neurofibrosarcoma of the gallbladder: a case report. World J Surg Oncol 2013;11:189.
[16] Odashiro AN, Pereira PR, Odashiro Muiji LN, Nguyen GK. Angiosarcoma of the gallbladder: case report and review of the literature. Can J Gastroenterol 2005;19:257–9.
[17] Costantini R, Di Bartolomeo N, Franchamano F, Angelucci D, Innocenti P. epitheloid angiosarcoma of the gallbladder: case report. J Gastrointest Surg 2005;9:822–5.
[18] Sánchez Acedo P, Herrera Cabezón J, Tarifa Castilla A, Zazpe Rípa C, Lera Tricas JM. epitheloid angiosarcoma of the gallbladder. Case report and review of the literature. An Sut Sanit Navar 2015;38:333–7.
[19] Husain EA, Prescott RJ, Haider SA, et al. Gallbladder sarcoma: a clinicopathological study of seven cases from the UK and Austria with emphasis on morphological subtypes. Dig Dis Sci 2009;54:395–400.
[20] Qayum A, Riaul TS, Sinivasan R, Salazar FA. A patient with synovial cell sarcoma primary to the gallbladder and common bile duct. J Gastrointest Surg 2008;12:609–11.
[21] Nestler G, Hallouz Z, Evert M, Dombrowski F, Lippert H, Meyer F. Myogenous sarcoma of the gallbladder with a hemangiopericytoma pattern. J Hepatobiliary Pancreat Surg 2007;14:197–9.
[22] Gahlot GP, Roy M, Jain H, et al. Primary extraskellet osteosarcoma of gall bladder. Trop Gastroenterol 2015;36:277–80.
[23] WHO Classification of Tumours Editorial Board·WHO Classification of Tumours of Soft Tissue and Bone. 5th ed.Lyon, France: IARC Press; 2020.
[24] Sharaglia M, Bellan E, Dei Tos AP. The 2020 WHO classification of soft tissue tumours: news and perspectives. Pathologica 2020;DOI 10.32074/1591-951X-213. [Online ahead of print].
[25] Fassier M, Gupta S, Jain R, Wadhwa D. carcinosarcoma of the gallbladder with heterologous differentiation: a case report. J Gastrointest Cancer 2015;46:175–7.
[26] Kim HH, Hur YH, Jeong EH, et al. carcinosarcoma of the gallbladder: report of two cases. Surg Today 2012;42:670–5.
[27] Wada Y, Takami Y, Tateishi M, et al. carcinosarcoma of the gallbladder: report of a case. J J Gastroenterol 2014;7:455–9.
[28] Okabayashi T, Sun ZL, Montgomery RA, Hanazaki K. Surgical outcome of carcinosarcoma of the gall bladder: a review. World J Gastroenterol 2009;15:4877–82.

Long et al. Medicine (2022) 101:2 Medicine
[29] Roa JC, Basturk O, Adsay V. Dysplasia and carcinoma of the gallbladder: pathologic evaluation, sampling, differential diagnosis and clinical implications. Histopathology 2021; DOI 10.1111/his.14360. [Online ahead of print].

[30] Igrec J, Fuchsjäger MH. Imaging of bone sarcomas and soft-tissue sarcomas. Rofo 2021; DOI 10.1055/a-1401-0215. [Online ahead of print].

[31] Behzadi AH, Raza SI, Carrino JA, et al. Applications of PET/CT and PET/MR Imaging in Primary Bone Malignancies. PET Clin 2018;13: 623–34.

[32] Bourcier K, Le Cesne A, Tselikas I, et al. Basic knowledge in soft tissue sarcoma. Cardiovasc Intervent Radiol 2019;42:1253–61.

[33] Bret PM, Labadie M, Bretagnolle M, Paliard P, Valette PJ. Hepatocellular carcinoma: diagnosis by percutaneous fine needle biopsy. Gastrointest Radiol 1988;13:253–5.

[34] Kim SH, Lim HK, Lee WJ, Cho JM, Jang HJ. Needle-tract implantation in hepatocellular carcinoma: frequency and CT findings after biopsy with a 19.5-gauge automated biopsy gun. Abdom Imaging 2000;25:246–50.

[35] Selby P, Popescu R, Lawler M, Butcher H, Costa A. The value and future developments of multidisciplinary team cancer care. Am Soc Clin Oncol Educ Book 2019;39:332–40.

[36] Popovich JR, Kashyap S, Cassaro S. Sarcoma. 2020. StatPearls [Internet] Treasure Island (FL): StatPearls Publishing; 2021.

[37] Huang D, Joo H, Song N, Cho S, Kim W, Shin A. Association between gallstones and the risk of biliary tract cancer: a systematic review and meta-analysis. Epidemiol Health 2021; e2021011. DOI 10.4178/epih.e2021011.

[38] Hatina J, Kripnerova M, Houfkova K, et al. Sarcoma stem cell heterogeneity. Adv Exp Med Biol 2019;1123:95–118.

[39] Morganti S, Tarantino P, Ferraro E, D’Amico P, Duso BA, Curigliano G. Next generation sequencing (NGS): a revolutionary technology in pharmacogenomics and personalized medicine in cancer. Adv Exp Med Biol 2019;1168:9–30.

[40] Italiano A. Is there value in molecular profiling of soft-tissue sarcoma? Curr Treat Options Oncol 2018;19:78.